A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. Howeve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Internal Medicine 2022/10/15, Vol.61(20), pp.3101-3106
Hauptverfasser: Numakura, Tadahisa, Murakami, Koji, Tamada, Tsutomu, Yamaguchi, Chiaki, Inoue, Chihiro, Ohkouchi, Shinya, Tode, Naoki, Sano, Hirohito, Aizawa, Hiroyuki, Sato, Kei, Mitsune, Ayumi, Kurosawa, Hajime, Nakazawa, Toru, Sugiura, Hisatoshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.0104-22